Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

How do we know PsA treatment is working?

Symptoms, examination, tests and everyday function: understanding response, low disease activity and remission.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 7 of 21

The essentials

Judge the trend across the areas that matter, using the same measures over time. A better blood test, clearer skin or less pain is useful information, but none alone describes the whole disease.

Set a starting point and a personal target

Before or near treatment initiation, record the active manifestations, examination findings and relevant tests. Choose a few everyday goals: fastening buttons, walking to a bus stop, sleeping or completing a shift. A brief note before each visit is usually more useful than checking every sensation repeatedly. 3

At follow-up, describe what improved, what did not and any new difficulty. Include doses actually taken, interruptions and adverse effects. These observations help distinguish a weak response from a treatment that has not had an adequate chance to work.

Agree when to reassess

Different medicines and manifestations need different times to respond. EULAR’s target-based approach seeks substantial improvement by about three months and the agreed target by about six months; these are clinical planning benchmarks, not instructions to tolerate deterioration until a deadline. 1

A review asks whether to continue, optimise, switch or investigate a different explanation. Arrange earlier contact for worsening, new swelling, an adverse effect or an access problem. Methotrexate may take up to about 12 weeks for its full benefit; that does not replace interim safety monitoring. 4

RV-PSA-04 · Aim for the Bullseye — Free after registration →

DAPSA, MDA and PsAID answer different questions

These tools organise information; they are not interchangeable and do not replace examination. Use a validated version with the care team. The table explains their purpose without reproducing a questionnaire or offering a self-treatment calculator.

DAPSA, MDA and PsAID answer different questions
Tool and focusWhat to remember
DAPSA — peripheral joint activityCombines 68 tender and 66 swollen joint counts, pain, patient global assessment and CRP. Skin, spine and entheses need separate assessment. 10
MDA — minimal disease activityRequires meeting at least five of seven criteria covering joints, skin, entheses, pain, patient global assessment and function. Some problems can remain; it does not directly assess axial disease. 11
PsAID — impact reported by the patientCaptures how the disease affects life, including pain, fatigue, skin concerns and daily function. A high impact score does not by itself prove active inflammation. 12

What tests and imaging add

CRP and ESR can help follow inflammation, but normal results do not exclude active PsA. Examination and the pattern of symptoms still matter. A blood test abnormality can also have another cause. 3

Ultrasound or MRI may answer a specific unresolved question about inflammation; X-rays are often used to assess structural changes. Imaging is not required at every visit and is not a universal tie-breaker for every painful area. Interpret results with the clinical question and previous studies. 3

Remission, low activity and reducing treatment

Remission is the intended absence or near-absence of active disease according to the clinical assessment and chosen definition. Low disease activity is a less stringent state. A score meeting a threshold should still be checked against skin, spine, other manifestations and your priorities. 1, 10, 11

Feeling better can mean that treatment is working, not that it is no longer needed. In sustained remission, carefully supervised tapering may be discussed. The plan needs a definition of stability, the proposed change, follow-up and what to do if symptoms return. It is not an automatic instruction to stop. 1

The road to target — Free after registration →

Go deeper

When the score and lived experience disagree

Imagine swelling has settled and laboratory results have improved, yet walking remains painful. That is a reason to examine the remaining problem, not to dismiss it. Conversely, tolerable pain does not prove that swollen joints are adequately controlled.

Ask to see both the overall trend and the individual components. Changes in joint activity, sleep, mood, accumulated damage and other health conditions may affect different measures in different ways. A shared explanation is more useful than arguing about which single number is “right.”

Questions for your visit

  1. What was my starting point, and which measures have changed?
  2. Does the score cover my skin, spine and tendon attachments?
  3. What explains symptoms that remain?
  4. What target and review date are we agreeing on now?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Drug approvals and availability vary by country. Regulatory updates are identified separately from older recommendations.

  1. Gossec L et al. EULAR recommendations for PsA: 2023 update. Ann Rheum Dis. 2024.
  2. NIAMS. Psoriatic arthritis: diagnosis, treatment and steps to take.
  3. American College of Rheumatology. Methotrexate: patient information. February 2025.
  4. Schoels MM et al. Defining remission and treatment success using DAPSA. Ann Rheum Dis. 2016.
  5. Coates LC et al. Defining minimal disease activity in PsA. Ann Rheum Dis. 2010.
  6. Gossec L et al. Psoriatic Arthritis Impact of Disease (PsAID): a 13-country EULAR initiative. Ann Rheum Dis. 2014.

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: PsoriasisPsoriatic arthritisSpondyloarthritis